Literature DB >> 9260976

Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition.

M Volpe1, P Magri, M A Rao, S Cangianiello, L DeNicola, A F Mele, B Memoli, I Enea, S Rubattu, B Gigante, B Trimarco, M Epstein, M Condorelli.   

Abstract

The onset and the mechanisms leading to Na+ retention in incipient congestive heart failure (CHF) have not been systematically investigated. To investigate renal Na+ handling in the early or mild stages of CHF, Na+ balance and renal clearances were assessed in 10 asymptomatic patients with idiopathic or ischemic dilated cardiomyopathy and mild heart failure (HF) off treatment (left ventricular ejection fraction, 29.7+/-2%) and in 10 matched normal subjects during a diet containing 100 mmol/d of NaCl and after 8 days of high salt intake (250 mmol/d). Six patients were studied again after 6 weeks of treatment with enalapril (5 mg/d P.O.). At the end of the high salt diet, in patients with mild HF the cumulative Na+ balance exceeded by 110 mmol that of normal subjects (F=3.86, P<.001). During high salt intake, renal plasma flow and glomerular filtration rate were similarly increased in both normal subjects and mild HF patients. In spite of comparable increases of filtered Na+ in the two groups, fractional excretion of Na+, fractional clearance of free water, and fractional excretion of K+ (indexes of distal delivery of Na+) increased in normal subjects and were reduced in patients with mild HF. During enalapril treatment, in the mild HF patients the cumulative Na+ balance was restored to normal; furthermore, enalapril significantly attenuated the abnormalities in the distal delivery of Na+. Our results indicate that a defective adaptation of Na+ reabsorption in the proximal nephron is associated with Na+ retention in response to increased salt intake in the early or mild stages of HF. These abnormalities of renal Na+ handling are largely reversed by enalapril.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260976     DOI: 10.1161/01.hyp.30.2.168

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study.

Authors:  Javed Butler; Lampros Papadimitriou; Vasiliki Georgiopoulou; Hal Skopicki; Sandra Dunbar; Andreas Kalogeropoulos
Journal:  Circ Heart Fail       Date:  2015-05       Impact factor: 8.790

Review 2.  CardioMEMS, the real progress in heart failure home monitoring.

Authors:  Edoardo Gronda; Emilio Vanoli; Alessandro Zorzi; Domenico Corrado
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

3.  Worsening of proteinuria caused by combination therapy of hypertonic saline and low-dose furosemide for treatment of acute decompensated heart failure with overt diabetic nephropathy.

Authors:  Koichi Nishimura; Shinichi Hirotani; Yoshitaka Okuhara; Tomotaka Ando; Daisuke Morisawa; Makiko Oboshi; Hisashi Sawada; Akiyo Eguchi; Toshihiro Iwasaku; Yoshiro Naito; Tohru Masuyama
Journal:  J Cardiol Cases       Date:  2015-08-28

4.  Fractional excretion of sodium predicts worsening renal function in acute decompensated heart failure.

Authors:  Fadi T Alattar; Nasha't Imran; Vincent A Debari; Kozhaya N Mallah; Fayez E Shamoon
Journal:  Exp Clin Cardiol       Date:  2010

5.  Can fractional excretion of sodium predict worsening of renal function, in-hospital mortality, and length of hospital stay in acute decompensated heart failure?

Authors:  Farzaneh Ahmadi; Ekhlas Torfi; Sayed Mohammadreza Afshani; Saadat Kazemi-Mansourabad; Fatemeh Hayati
Journal:  ARYA Atheroscler       Date:  2021-11

6.  Urinary composition predicts diuretic efficiency of hypertonic saline solution with furosemide therapy and heart failure prognosis.

Authors:  Tomotaka Ando; Yoshitaka Okuhara; Yoshiyuki Orihara; Koichi Nishimura; Kyoko Yamamoto; Tohru Masuyama; Shinichi Hirotani
Journal:  Heart Vessels       Date:  2018-03-19       Impact factor: 2.037

7.  Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study.

Authors:  Yoshitaka Okuhara; Shinichi Hirotani; Tomotaka Ando; Koichi Nishimura; Yoshiyuki Orihara; Kazuo Komamura; Yoshiro Naito; Toshiaki Mano; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-07-28       Impact factor: 2.037

Review 8.  The prognostic significance of renal dysfunction in patients with chronic systolic heart failure.

Authors:  S Raja Laskar; Daniel L Dries
Journal:  Curr Cardiol Rep       Date:  2003-05       Impact factor: 2.931

9.  Effect of fluid and dietary sodium restriction in the management of patients with heart failure and preserved ejection fraction: study protocol for a randomized controlled trial.

Authors:  Karina S M d'Almeida; Eneida R Rabelo-Silva; Gabriela C Souza; Melina M Trojahn; Sofia L S Barilli; Jessica V Mansson; Andreia Biolo; Luis E P Rohde; Nadine Clausell; Luís Beck-da-Silva
Journal:  Trials       Date:  2014-09-04       Impact factor: 2.279

10.  A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.

Authors:  S de Denus; J L Rouleau; D L Mann; G S Huggins; T P Cappola; S H Shah; J Keleti; Y F Zada; S Provost; A Bardhadi; M S Phillips; V Normand; I Mongrain; M-P Dubé
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.